HeartHero AED Submitted for FDA Premarket Approval

March 10, 2026 — HeartHero has announced that its Premarket Approval (PMA) application for Elliot, the company’s connected Automated External Defibrillator (AED), has been submitted to and accepted for review by the U.S. Food and Drug Administration (FDA). Elliot is regulated as a Class III medical device, the FDA’s highest-risk and most rigorously evaluated category for life-sustaining technologies.

For cardiac arrests, the weakest link in the chain of survival has always been time to shock. When an AED shock is delivered within three minutes, the chance of survival is better than 70%. However, in the time that it takes for Emergency Medical Services to arrive with an AED, it’s often too late. For decades, defibrillator deployment strategies centered primarily on buildings, yet approximately 80% of sudden cardiac arrests occur in the home, where immediate access to defibrillators has not been readily available.

“In trauma, time allows transport. In cardiac arrest, time determines survival. Having our Class III PMA accepted for review reflects our commitment to meeting the most stringent regulatory standards while expanding access wherever seconds matter most,” said Gary Montague, founder and CEO of HeartHero and former CIA medical officer.

Elliot is engineered to reduce time to shock while remaining practical for everyday environments, including family homes. Weighing just over one pound, the device provides guided voice prompts to assist bystanders during cardiac emergencies and analyzes heart rhythm to deliver a shock when clinically appropriate. Elliot operates on widely available CR123 lithium batteries, including store-bought Duracell options, eliminating dependence on proprietary power systems and supporting long-term readiness in both residential and community settings.

The device integrates with a companion mobile application designed to enhance user confidence through training resources, device status reporting, and readiness monitoring, reinforcing preparedness beyond the moment of emergency. HeartHero is currently selling and distributing units in the United Kingdom and Australia.

The FDA’s Premarket Approval requires extensive clinical and engineering evidence, validated manufacturing controls, and comprehensive review of safety and effectiveness data. Acceptance for review confirms that a device has met the FDA’s threshold for full scientific evaluation under these rigorous standards. Review timelines are determined by the agency as part of its regulatory process.

HeartHero previously secured CE Mark certification in the European Union and United Kingdom, is registered with Australia’s Therapeutic Goods Administration (TGA), and operates under United Kingdom regulatory oversight through the Medicines and Healthcare products Regulatory Agency (MHRA).

HeartHero continues expanding global access while advancing U.S. regulatory review.